Evidence map›Paper›PMID 39232731›Full record

ArticleWorld journal of surgical oncology2024

Impact on survival of sarcopenia, systemic inflammatory response and anthropometric factors after pancreatectomy for resectable pancreatic adenocarcinoma.

Kaja Balcer, Jonathan Garnier, Yasmina Richa, Christophe Bruneel-Zupanc, Guillaume Piessen, Olivier Turrini, Stephanie Truant, Mehdi El Amrani

Abstract read
In one paragraph

Article in World journal of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kaja BalcerDigestive Surgery and Transplantation Department, CHU de Lille, University of Lille, Lille, 59000, France. kaja.balcer@gmail.com.
Jonathan GarnierDepartment of Surgical Oncology, Institut Paoli-Calmettes, Marseille, 13009, France.
Yasmina RichaSchool of Medicine, University College Cork, Cork, Ireland.
Christophe Bruneel-ZupancDepartment of Economics, KU Leuven, Leuven, Belgium.
Guillaume PiessenDepartment of Digestive and Oncological Surgery, University of Lille, CNRS, INSERM, CHU Lille, University of Lille, Lille, 59000, France.
Olivier TurriniDepartment of Surgical Oncology, Institut Paoli-Calmettes, Marseille, 13009, France.
Stephanie TruantDigestive Surgery and Transplantation Department, CHU de Lille, University of Lille, Lille, 59000, France.
Mehdi El AmraniDigestive Surgery and Transplantation Department, CHU de Lille, University of Lille, Lille, 59000, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPancreatic adenocarcinoma (PDAC) is becoming a public health issue with a 5-years survival rate around 10%. Patients with PDAC are often sarcopenic, which impacts postoperative outcome. At the same time, overweight population is increasing and adipose tissue promotes tumor related-inflammation. With several studies supporting independently these data, we aimed to assess if they held an impact on survival when combined.

methodsWe included 232 patients from two university hospitals (CHU de Lille, Institut Paoli Calmette), from January 2011 to December 2018, who underwent Pancreaticoduodenectomy (PD) for resectable PDAC. Preoperative CT scan was used to measure sarcopenia and visceral fat according to international cut-offs. Neutrophil to lymphocyte (NLR) and platelet to lymphocyte ratios (PLR) were used to measure inflammation. For univariate and multivariate analyses, the Cox proportional-hazard model was used. P-values below 0.05 were considered significant.

resultsSarcopenic patients with visceral obesity were less likely to survive than the others in multivariate analysis (OS, HR 1.65, p= 0.043). Cutaneous obesity did not influence survival. We also observed an influence on survival when we studied sarcopenia with visceral obesity (OS, p= 0.056; PFS, p = 0.014), sarcopenia with cutaneous obesity (PFS, p= 0.005) and sarcopenia with PLR (PFS, p= 0.043). This poor prognosis was also found in sarcopenic obese patients with high PLR (OS, p= 0.05; PFS, p= 0.01).

conclusionSarcopenic obesity was associated with poor prognosis after PD for PDAC, especially in patients with systemic inflammation. Pre operative management of these factors should be addressed in pancreatic cancer patients.

Indexed as

AdenocarcinomaPancreatectomyPancreatic NeoplasmsSarcopeniaAgedCarcinoma, Pancreatic DuctalFemaleFollow-Up StudiesHumansMaleMiddle AgedPancreaticoduodenectomyPrognosisRetrospective StudiesSurvival RateSystemic Inflammatory Response SyndromeObesityPancreatic adenocarcinomaSarcopeniaSystemic inflammatory response

Identifiers

PMID39232731
PMCPMC11376042

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.